OVID Overview

Appointment Announcement: Ovid Therapeutics Inc. has appointed Petra Kaufmann as its new chief medical officer.

Professional Background: Kaufmann has significant experience in the biopharmaceutical sector and previously led rare-disease research initiatives at the U.S. National Institutes of Health.

Previous Role: Before joining Ovid, she was the Chief Medical Officer at Vigil Neuroscience, which was recently acquired by Sanofi.

Expertise Areas: In her previous role, Kaufmann managed various functions including medical, clinical, biomarker, patient advocacy, and regulatory aspects.

Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.

Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.

Market Intelligence: Benzinga Pro is positioned as a source for the fastest and most accurate stock market intelligence available.

Analyst Coverage Initiations: BTIG analyst Thomas Shrader initiated coverage on Alto Neuroscience (ANRO) with a Buy rating and a price target of $27, while B of A Securities analyst Travis Steed gave Masimo Corporation (MASI) a Neutral rating with a target of $162.

Ovid Therapeutics and Vivos Therapeutics Ratings: Leerink Partners analyst Marc Goodman rated Ovid Therapeutics (OVID) as Outperform with a price target of $5, and HC Wainwright & Co. analyst Yi Chen rated Vivos Therapeutics (VVOS) as Buy with a target of $7.

TAT Technologies Coverage: Benchmark initiated coverage on TAT Technologies Ltd. (TATT) with a Buy rating and a price target of $53.

Current Stock Prices: As of Friday, Alto Neuroscience closed at $12.11, Masimo at $151.12, Ovid at $1.3050, Vivos at $2.34, and TAT Technologies at $40.04.